SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Phase 1

Completed

Conditions: Diphtheria Immunisation (Healthy Volunteers)
Tetanus Immunisation (Healthy Volunteers)
Pertussis Immunisation (Healthy Volunteers)

Interventions: Biological: Licensed Tdap vaccine
Biological: Investigational Tdap vaccine Formulation A
Biological: Investigational Tdap vaccine Formulation C
Biological: Investigational Tdap vaccine Formulation B
Biological: Investigational Tdap vaccine Formulation D

First Posted Date: 2019-05-22

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 71

Registration Number: NCT03958799

Locations: 🇨🇦
Investigational Site Number 1240006, Halifax, Canada
🇨🇦
Investigational Site Number 1240003, Truro, Canada
🇨🇦
Investigational Site Number 1240004, Quebec, Canada

and more 2 locations

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Phase 3

Completed

Conditions: Meningococcal Immunisation (Healthy Volunteers)

Interventions: Biological: Meningococcal group C polysaccharide Conjugate vaccine adsorbed
Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine
Biological: Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine

First Posted Date: 2019-03-26

Last Posted Date: 2023-09-26

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 707

Registration Number: NCT03890367

Locations: 🇫🇮
Investigational Site Number 2460006, Espoo, Finland
🇩🇪
Investigational Site Number 2760019, Bretten, Germany
🇩🇪
Investigational Site Number 2760017, Hamburg, Germany

and more 26 locations

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

Phase 3

Completed

Conditions: Healthy Volunteers (Meningococcal Infection)

Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine

First Posted Date: 2019-03-11

Last Posted Date: 2025-03-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 290

Registration Number: NCT03869866

Locations: 🇱🇧
Investigational Site Number : 4220001, Beirut, Lebanon
🇹🇷
Investigational Site Number : 7920002, Ankara, Turkey
🇹🇷
Investigational Site Number : 7920001, Ankara, Turkey

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Quadrivalent Influenza Vaccine

First Posted Date: 2018-12-05

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 230

Registration Number: NCT03765437

Locations: 🇻🇳
Investigational Site Number 7040001, Viet Tri, Vietnam

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year

Phase 3

Completed

Conditions: Healthy Volunteers (Rabies Immunization)

Interventions: Biological: HDCV
Biological: PVRV

First Posted Date: 2018-10-09

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 570

Registration Number: NCT03700242

Locations: 🇵🇭
Investigational Site Number 001, Muntinlupa, Philippines
🇵🇭
Investigational Site Number 002, Cebu City, Philippines

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
Biological: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)
Biological: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
Biological: Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)
Biological: FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)

First Posted Date: 2018-10-05

Last Posted Date: 2022-04-04

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 665

Registration Number: NCT03698279

Locations: 🇺🇸
Investigational Site Number 8400001, Miami, Florida, United States
🇺🇸
Investigational Site Number 8400002, Atlanta, Georgia, United States
🇺🇸
Investigational Site Number 8400015, Newton, Kansas, United States

and more 13 locations

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Phase 3

Completed

Conditions: Healthy Volunteers (Meningococcal Infection)

Interventions: Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine
Biological: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine
Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine
Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine
Biological: Haemophilus b Conjugate Vaccine
Biological: Pneumococcal 13-valent Conjugate Vaccine
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
Biological: Hepatitis B Vaccine
Biological: Measles, Mumps, and Rubella Virus Vaccine Live
Biological: Varicella Virus Vaccine Live

First Posted Date: 2018-10-02

Last Posted Date: 2024-06-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 950

Registration Number: NCT03691610

Locations: 🇺🇸
Emmaus Research Center, Inc Site Number : 8400019, Anaheim, California, United States
🇺🇸
Brownsboro Park Pediatrics Site Number : 8400039, Louisville, Kentucky, United States
🇺🇸
Velocity Clinical Research Site Number : 8400016, Metairie, Louisiana, United States

and more 44 locations

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Phase 3

Completed

Conditions: Healthy Volunteers (Meningococcal Infection)

Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)
Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)
Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine
Biological: Pneumococcal 13-valent Conjugate Vaccine
Biological: Rotavirus Vaccine
Biological: Hepatitis B Vaccine
Biological: Measles, Mumps, and Rubella Virus Vaccine
Biological: Varicella Virus Vaccine

First Posted Date: 2018-09-17

Last Posted Date: 2023-12-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2797

Registration Number: NCT03673462

Locations: 🇺🇸
Senders Pediatrics-Site Number:8400061, South Euclid, Ohio, United States
🇺🇸
Southeastern Pediatric Associates-Site Number:8400034, Dothan, Alabama, United States
🇺🇸
De Armas Research Center,-Site Number:8400088, Miami, Florida, United States

and more 66 locations

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico

Phase 3

Completed

Conditions: Healthy Volunteers (Meningococcal Infection)

Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological: Measles, Mumps, and Rubella Virus Vaccine Live
Biological: Pneumococcal 13-valent Conjugate Vaccine
Biological: Rotavirus Vaccine, Live, Pentavalent
Biological: Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine
Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine
Biological: Hepatitis B Vaccine

First Posted Date: 2018-08-15

Last Posted Date: 2023-10-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 525

Registration Number: NCT03630705

Locations: 🇷🇺
Investigational Site Number :6431008, Krasnodar, Russian Federation
🇷🇺
Investigational Site Number :6431004, Perm, Russian Federation
🇲🇽
Investigational Site Number :4840002, Mexico City, Ciudad De Mexico, Mexico

and more 8 locations

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Phase 3

Completed

Conditions: Healthy Volunteers (Meningococcal Infection)

Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine
Biological: Meningococcal group B vaccine
Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
Biological: Human rotavirus RIX4414 strain vaccine
Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine

First Posted Date: 2018-08-15

Last Posted Date: 2023-11-07

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 788

Registration Number: NCT03632720

Locations: 🇬🇧
Investigational Site Number :8260002, London, United Kingdom
🇬🇧
Investigational Site Number :8260021, Waterlooville, United Kingdom
🇬🇧
Investigational Site Number :8260004, Manchester, United Kingdom

and more 10 locations

Home Terms & Conditions Privacy Policy